Drug Trial Radar · NCT03031262
Efficacy and Safety of Chidamide in CBF Leukemia
Last checked: Nov 20, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Feb 8, 2017
Primary completion
Apr 10, 2025
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC) or high-dose cytarabine plus chidamide.The safety and efficacy of chidamide is evaluated.
Conditions
- AML
Interventions
CytarabineDrug
Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
ChidamideDrug
Chidamide at a dose of 20mg/d twice a week for 3 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relapse-Free Survival Rate (RFS)Time frame: Within 5 years after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.